Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine B Winfree

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Journal of Medical Economics|November 30, 2023
Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancerSory Traore, Andreas Sashegyi, Katherine B Winfree, et al.
Current Medical Research and Opinion|September 21, 2021
Study of patient characteristics, treatment patterns, <i>EGFR</i> testing patterns and outcomes in real-world patients with <i>EGFR</i>m<sup>+</sup> non-small cell lung cancerKatherine B Winfree, Kristin M Sheffield, Zhanglin Lin Cui, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2013
Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient settingManan Shah, Katherine B Winfree, Patrick Peterson, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancerMaurice Pérol, Katherine B Winfree, Gebra Cuyun Carter, et al.
Journal of Comparative Effectiveness Research|January 9, 2023
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancerHimani Aggarwal, Kerigo Ndirangu, Katherine B Winfree, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2015
Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.SGayathri Kumar, Beth Woods, Lisa M Hess, et al.
Current Medical Research and Opinion|November 14, 2018
Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world settingKatherine B Winfree, Aracelis Z Torres, Yajun Emily Zhu, et al.
Acta Haematologica|May 20, 2024
Racial and Ethnic Characteristics and Outcomes of Patients Diagnosed with CLL/SLL in the USADebora S Bruno, Manoj Khanal, Xiaohong I Li, et al.
Journal of Medical Economics|August 29, 2025
Continuity of care for patients with chronic lymphocytic leukemia: an analysis of real-world dataSameh Gabella, Manoj Khanal, Yongmei Chen, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 2, 2017
A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in FranceKaisa Taipale, Katherine B Winfree, Mark Boye, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Journal of Medical Economics|November 30, 2023
Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancerSory Traore, Andreas Sashegyi, Katherine B Winfree, et al.
Current Medical Research and Opinion|September 21, 2021
Study of patient characteristics, treatment patterns, <i>EGFR</i> testing patterns and outcomes in real-world patients with <i>EGFR</i>m<sup>+</sup> non-small cell lung cancerKatherine B Winfree, Kristin M Sheffield, Zhanglin Lin Cui, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2013
Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient settingManan Shah, Katherine B Winfree, Patrick Peterson, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancerMaurice Pérol, Katherine B Winfree, Gebra Cuyun Carter, et al.
Journal of Comparative Effectiveness Research|January 9, 2023
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancerHimani Aggarwal, Kerigo Ndirangu, Katherine B Winfree, et al.
Lung Cancer (Amsterdam, Netherlands)|July 1, 2015
Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.SGayathri Kumar, Beth Woods, Lisa M Hess, et al.
Current Medical Research and Opinion|November 14, 2018
Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world settingKatherine B Winfree, Aracelis Z Torres, Yajun Emily Zhu, et al.
Acta Haematologica|May 20, 2024
Racial and Ethnic Characteristics and Outcomes of Patients Diagnosed with CLL/SLL in the USADebora S Bruno, Manoj Khanal, Xiaohong I Li, et al.
Journal of Medical Economics|August 29, 2025
Continuity of care for patients with chronic lymphocytic leukemia: an analysis of real-world dataSameh Gabella, Manoj Khanal, Yongmei Chen, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 2, 2017
A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in FranceKaisa Taipale, Katherine B Winfree, Mark Boye, et al.
Pageof 4